- Definition: temp ≥38.3 °C once (or ≥38.0 °C for 1 h) + ANC <500 (or <1000 expected to fall <500).
- Antibiotics within 60 minutes: cefepime 2 g q8h (or pip-tazo / meropenem). Draw 2 sets of blood cultures first (one from each lumen of a line).
- Add vancomycin only for: shock, catheter infection, skin/soft-tissue infection, pneumonia, MRSA colonization, gram-positives in blood.
- Signs of infection may be absent — no neutrophils = no pus, no infiltrate, no pyuria.
- MASCC ≥21 = low risk → may qualify for oral therapy/outpatient (with oncology).
Pathophysiology in 60 seconds
⌄
- Chemotherapy kills fast-dividing cells: neutrophils (nadir day 7–14) and gut lining (mucositis) → gut bacteria translocate.
- Gram-negative rods (Pseudomonas, E. coli, Klebsiella) kill fastest → the empiric drug must cover Pseudomonas.
- Longer neutropenia (>7 days) → fungi (Candida, Aspergillus).
Diagnosis & workup
⌄
- Full exam: mouth, skin, line sites, perianal area (look, no rectal exam), lungs, sinuses.
- Labs: CBC with diff, CMP, lactate, blood cultures ×2, UA + urine culture, CXR, respiratory viral PCR as indicated, C. diff if diarrhea.
- CT chest if respiratory symptoms (CXR is often normal); CT sinuses if symptoms.
| MASCC (selected items) | Points |
|---|---|
| Burden of illness: none/mild | 5 |
| No hypotension | 5 |
| No COPD | 4 |
| Solid tumor or no prior fungal infection | 4 |
| No dehydration | 3 |
| Outpatient at onset | 3 |
| Age <60 | 2 |
| ≥21 = low risk |
Management
⌄
| Situation | Regimen |
|---|---|
| Standard | Cefepime 2 g IV q8h · or pip-tazo 4.5 g q6h · or meropenem 1 g q8h |
| Penicillin allergy (severe) | Aztreonam + vancomycin (± aminoglycoside) |
| Add vancomycin | Shock, suspected line infection, SSTI, pneumonia, MRSA colonization, GPC in blood |
| Abdominal source / C. diff risk | Pip-tazo or meropenem (+ oral vanc if C. diff) |
| Low risk, outpatient (MASCC ≥21) | Ciprofloxacin + amoxicillin-clavulanate (if no FQ prophylaxis) |
- Fever 3–5 days is common — do not change antibiotics just for fever if stable.
- Fever >4–7 days with expected long neutropenia → CT chest, galactomannan/β-D-glucan, start empiric antifungal (voriconazole/echinocandin/liposomal amphotericin).
- Clinical worsening → broaden (meropenem, + vanc, + antifungal).
- Unexplained fever: continue until afebrile ≥48 h and ANC recovering (>500) — or stop earlier if clinically stable and afebrile ≥72 h (ECIL-4 approach, with expert input).
- Documented infection: treat that infection's standard course.
- G-CSF not routine for established febrile neutropenia (consider in high-risk sepsis).
Pitfalls
⌄
- Waiting for the CBC result before antibiotics in a febrile chemo patient.
- Rectal temperatures/exams (bacteremia risk).
- Reflex vancomycin for every case.
- Forgetting antifungal coverage after a week of fever.
Board corner
⌄
| Stem | Answer |
|---|---|
| Fever 38.6, ANC 200, BP normal | Cefepime within 1 h |
| Same + hypotension | Add vancomycin (± broaden to meropenem) |
| Day 6 of fever, nodules with halo sign on CT | Invasive aspergillosis → voriconazole |
| Neutropenic, RLQ pain, bowel wall thickening | Neutropenic enterocolitis (typhlitis) |
References
⌄
- Taplitz RA, et al. Outpatient Management of Fever and Neutropenia: ASCO/IDSA Guideline. J Clin Oncol. 2018;36:1443.
- Freifeld AG, et al. IDSA Guideline for Neutropenic Patients with Cancer. Clin Infect Dis. 2011;52:e56.
- Klastersky J, et al. MASCC risk index. J Clin Oncol. 2000.